$PHIO
Phio Pharmaceuticals Corp.

2015 Q3 Form 10-Q Financial Statement

#000119312515287233 Filed on August 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $12.00K
YoY Change -100.0% -100.0% -94.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $770.0K $800.0K $850.0K
YoY Change 0.0% -5.88% -107.54%
% of Gross Profit
Research & Development $1.734M $1.361M $1.183M
YoY Change 18.85% 15.05% -2.47%
% of Gross Profit
Depreciation & Amortization $20.00K $20.00K $20.00K
YoY Change -33.33% 0.0% 0.0%
% of Gross Profit
Operating Expenses $2.504M $2.165M $2.033M
YoY Change 12.54% 6.49% -7.17%
Operating Profit -$2.504M -$2.165M -$2.021M
YoY Change 13.35% 7.13% 2.85%
Interest Expense $8.000K $1.000K $5.000K
YoY Change 100.0% -80.0% 25.0%
% of Operating Profit
Other Income/Expense, Net $8.000K -$1.000K $15.00K
YoY Change 166.67% -106.67%
Pretax Income -$2.500M -$2.170M -$2.010M
YoY Change 13.12% 7.96% 2.55%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$2.496M -$2.166M -$2.006M
YoY Change 13.15% 7.98% 2.29%
Net Earnings / Revenue -16716.67%
Basic Earnings Per Share
Diluted Earnings Per Share -$250.0M -$217.0M -$1.263B
COMMON SHARES
Basic Shares Outstanding 64.95M shares 36.16M shares 14.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.04M $13.99M $11.91M
YoY Change 18.85% 17.46% -32.29%
Cash & Equivalents $4.035M $5.986M $11.91M
Short-Term Investments $8.000M $8.000M $0.00
Other Short-Term Assets $480.0K $770.0K $420.0K
YoY Change -14.29% 83.33% 61.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $12.52M $14.75M $12.33M
YoY Change 17.09% 19.68% -30.93%
LONG-TERM ASSETS
Property, Plant & Equipment $162.0K $181.0K $204.0K
YoY Change -16.06% -11.27% 38.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $18.00K $18.00K $18.00K
YoY Change 0.0% 0.0%
Total Long-Term Assets $180.0K $199.0K $222.0K
YoY Change -14.69% -10.36% 51.02%
TOTAL ASSETS
Total Short-Term Assets $12.52M $14.75M $12.33M
Total Long-Term Assets $180.0K $199.0K $222.0K
Total Assets $12.70M $14.95M $12.55M
YoY Change 16.48% 19.15% -30.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $222.0K $635.0K $293.0K
YoY Change 62.04% 116.72% -18.16%
Accrued Expenses $1.443M $1.187M $682.0K
YoY Change 50.63% 74.05% -25.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.665M $1.822M $1.053M
YoY Change 44.03% 73.03% -30.26%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.665M $1.822M $1.053M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.670M $1.820M $1.050M
YoY Change 43.97% 73.33% -30.46%
SHAREHOLDERS EQUITY
Retained Earnings -$54.49M -$51.99M -$42.37M
YoY Change 22.23% 22.71%
Common Stock $6.000K $6.000K $1.000K
YoY Change 200.0% 500.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.03M $13.13M $6.562M
YoY Change
Total Liabilities & Shareholders Equity $12.70M $14.95M $12.55M
YoY Change 16.48% 19.15% -30.26%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$2.496M -$2.166M -$2.006M
YoY Change 13.15% 7.98% 2.29%
Depreciation, Depletion And Amortization $20.00K $20.00K $20.00K
YoY Change -33.33% 0.0% 0.0%
Cash From Operating Activities -$1.970M -$1.800M -$2.020M
YoY Change 11.93% -10.89% -1.46%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$30.00K -$70.00K
YoY Change -100.0% -57.14%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$8.000M $3.010M
YoY Change -100.0% -365.78% -133.44%
Cash From Investing Activities $0.00 -$8.030M $2.940M
YoY Change -100.0% -373.13% -132.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $9.200M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 9.240M 1.980M
YoY Change 366.67% 19700.0%
NET CHANGE
Cash From Operating Activities -1.970M -1.800M -2.020M
Cash From Investing Activities 0.000 -8.030M 2.940M
Cash From Financing Activities 10.00K 9.240M 1.980M
Net Change In Cash -1.960M -590.0K 2.900M
YoY Change -71.05% -120.34% -126.27%
FREE CASH FLOW
Cash From Operating Activities -$1.970M -$1.800M -$2.020M
Capital Expenditures $0.00 -$30.00K -$70.00K
Free Cash Flow -$1.970M -$1.770M -$1.950M
YoY Change 13.22% -9.23% -4.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
64949121 shares
CY2015Q2 rxii Sale Of Unit Price Per Share
SaleOfUnitPricePerShare
0.40
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11911000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3333678 shares
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
64949121 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2218862 shares
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
64949121 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.38
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
13131000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65118000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
635000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1187000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51993000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14953000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1822000
CY2015Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2015Q2 us-gaap Assets
Assets
14953000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
181000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
14754000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
718000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5986000
CY2015Q2 us-gaap Short Term Investments
ShortTermInvestments
8000000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30323
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11390000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3000264 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.39
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21984272 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21984272 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
2745000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
48047000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
47000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
285000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1002000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-46882000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9189000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1334000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000
CY2014Q4 us-gaap Assets
Assets
9189000
CY2014Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
183000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
8988000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
442000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8496000
CY2015Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9200000
CY2015Q2 rxii Gross Proceeds From Issuance Of Common Stock
GrossProceedsFromIssuanceOfCommonStock
10400000
CY2015Q2 rxii Sale Of Unit Number Of Shares
SaleOfUnitNumberOfShares
26000000 shares
CY2015Q2 rxii Sale Of Unit Description Of Transaction
SaleOfUnitDescriptionOfTransaction
Each unit consists of one share of common stock, a 13-month overallotment purchase right to purchase one-half of one share of common stock at a price of $0.455 per full share of common stock (the "Overallotment Purchase Rights") and a five-year warrant to purchase one-half of one share of common stock at a price of $0.52 per full share of common stock (the "Warrants").
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4397000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25559710 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0701 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0160 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0273 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0119 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9791 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13319634 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
71000
us-gaap Net Income Loss
NetIncomeLoss
-4290000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7258000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
11000
us-gaap Revenue From Grants
RevenueFromGrants
41000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4311000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
21000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
13200
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
10000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2968000
us-gaap Share Based Compensation
ShareBasedCompensation
948000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
333000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
30000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-40000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
521000
us-gaap Operating Expenses
OperatingExpenses
4352000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
2941000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
3000000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1977000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2659000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1947000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1113000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1693000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1025000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
130000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42000
rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
46600
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3772000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
21250 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Amendment Flag
AmendmentFlag
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29303293 shares
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001533040
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M9D
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
2.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8762 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9116 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.56
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
RXi Pharmaceuticals Corp
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
354664 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0147 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.41
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0183 pure
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <i>Uses of Estimates in Preparation of Financial Statements</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</p> </div>
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2510000
us-gaap Operating Expenses
OperatingExpenses
5145000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8039000
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
228000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9301000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16000
dei Trading Symbol
TradingSymbol
RXII
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8563 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
34033463 shares
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
us-gaap Net Income Loss
NetIncomeLoss
-5111000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5320000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2000
us-gaap Revenue From Grants
RevenueFromGrants
34000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
276000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5111000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
13000
us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
8000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
209000
us-gaap Share Based Compensation
ShareBasedCompensation
858000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
127000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
31000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-47000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
6814000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
350000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
41000
rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
-21800
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3468000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9254000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
185000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1677000
CY2014Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0164 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0160 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.26
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0195 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
1.0077 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9791 pure
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14015451 shares
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-2006000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3219000
CY2014Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5000
CY2014Q2 us-gaap Revenue From Grants
RevenueFromGrants
12000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2021000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
15000
CY2014Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6600
CY2014Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1213000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
457000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
2033000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1183000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
850000
CY2014Q2 rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
9600
CY2015Q2 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
35000 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2015Q2 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8791 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0155 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.28
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0183 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.8685 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8563 pure
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44190583 shares
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-2166000
CY2015Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2190000
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2165000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1000
CY2015Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
6500
CY2015Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
24000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
447000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
2165000
CY2015Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
16000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1361000
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
804000
CY2015Q2 rxii Nonemployee Share Based Compensation Expense Income
NonemployeeShareBasedCompensationExpenseIncome
-5300

Files In Submission

Name View Source Status
0001193125-15-287233-index-headers.html Edgar Link pending
0001193125-15-287233-index.html Edgar Link pending
0001193125-15-287233.txt Edgar Link pending
0001193125-15-287233-xbrl.zip Edgar Link pending
d58449d10q.htm Edgar Link pending
d58449dex311.htm Edgar Link pending
d58449dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rxii-20150630.xml Edgar Link completed
rxii-20150630.xsd Edgar Link pending
rxii-20150630_cal.xml Edgar Link unprocessable
rxii-20150630_def.xml Edgar Link unprocessable
rxii-20150630_lab.xml Edgar Link unprocessable
rxii-20150630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending